New drug combo aims to shrink Hard-to-Treat tumors

NCT ID NCT06848699

Recruiting now Disease control Sponsor: Shanghai Henlius Biotech Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new combination of two drugs (HLX43 and Serplulimab) in people with advanced or metastatic solid tumors, including non-small cell lung cancer. The goal is to find the safest dose and see if the treatment can shrink tumors. About 105 adults aged 18 to 75 who have not responded to standard treatments will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer metastatic malignant neoplasm neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL-CELL LUNG CANCER SOLID TUMOR CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Hunan Provincial Cancer Hospital
RECRUITING

Hunan, Changsha, 410031, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Second Affiliated Hospital of Army Medical University, PLA
RECRUITING

Chongqing, 400000, China

Contact
Shandong Cancer Hospital
RECRUITING

Jinan, Shangdong, China